Parenteral 17beta-estradiol decreases fasting blood glucose levels in non-obese mice with short-term ovariectomy

Kim, Ju‐Young; Jo, Kyung-Jin; Kim, Ok-Soon; Kim, Byung-Joon; Kang, Dong-Wook; Lee, Kiho; Baik, Haing-Woon; Han, Moonsik; Lee, Seong-Kyu

doi:10.1016/j.lfs.2010.07.009

Cited by 46 publications

(28 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with this result, previous studies showed that E 2 injection increased the expression of PPARa, AMPK, and CPT1 in liver and/or skeletal muscle (D'Eon et al 2005;Paquette et al 2008;Kim et al 2010).…”

Section: Discussionsupporting

confidence: 87%

Estrogen and n-3 polyunsaturated fatty acid supplementation have a synergistic hypotriglyceridemic effect in ovariectomized rats

2015

View full text Add to dashboard Cite

The n-3 polyunsaturated fatty acids (PUFAs), EPA and DHA, as well as estrogen have been shown to decrease circulating levels of triglyceride (TG), but their underlying mode of action is unclear. The purpose of this study was to determine the effects of n-3 PUFA consumption and estrogen injection on TG metabolism. Rats (n = 48) were fed a modified AIN-93G diet with 0, 1, or 2 % EPA ? DHA relative to the total energy intake during 12 weeks. At 8 weeks, rats were ovariectomized (OVX), and after a 1-week recovery, rats were injected with either 17b-estradiol-3-benzoate (E 2 ) or corn oil for the last 3 weeks. The n-3 PUFA consumption and E 2 injection independently decreased the hepatic expressions of sterol regulatory element-binding protein 1, acetyl-CoA carboxylase 1, fatty acid synthase (FAS), and diacylglycerol acyltransferase 2 (DGAT2) (P \ 0.05). There were interactions between n-3 PUFA consumption and E 2 injection on hepatic expression of FAS and DGAT2. In addition, n-3 PUFA consumption and E 2 injection upregulated the expression of AMP-activated protein kinase (AMPK), phosphorylated AMPK, peroxisomal proliferator-activated receptor a, and carnitine palmitoyltransferase 1 in liver and skeletal muscle. E 2 injection increased the expression of estrogen receptor a and b in skeletal muscle and liver, but n-3 PUFA consumption increased the expression of both receptors only in skeletal muscle. The present study suggests that the hypotriglyceridemic effects of n-3 PUFA consumption and E 2 injection could be due to the down-regulation of hepatic TG synthesis and upregulation of TG oxidation in liver and skeletal muscle in OVX rats.

show abstract

Section: Discussionsupporting

confidence: 87%

Estrogen and n-3 polyunsaturated fatty acid supplementation have a synergistic hypotriglyceridemic effect in ovariectomized rats

2015

View full text Add to dashboard Cite

show abstract

“…36,37 In rodents, ovariectomy is accompanied by reduced skeletal muscle AMPK activity, and restored by E 2 treatment. 38 Moreover, acute (10 minutes) E 2 stimulation of rat soleus muscle in vitro increased AMPK. 18 This latter observation is consistent with a rapid nongenomic action of E 2 on AMPK-mediated pathways.…”

Section: Discussionmentioning

confidence: 97%

Time since menopause and skeletal muscle estrogen receptors, PGC-1α, and AMPK

Park¹,

Pereira

Erickson³

et al. 2017

Menopause

View full text Add to dashboard Cite

Objective:Short-term administration of estradiol (E2) improves insulin-stimulated glucose disposal rate in early postmenopausal (EPM) women compared with a reduction in late postmenopausal (LPM) women. The underlying mechanisms by which E2 action on glucose disposal rate reversed from beneficial early to harmful late in menopause is unknown, but might include adverse changes in estrogen receptors (ERs) or other biomarkers of cellular energy metabolism with age or duration of estrogen deficiency.Methods:We retrospectively analyzed skeletal muscle samples from 27 postmenopausal women who were 6 years or less past menopause (EPM; n = 13) or at least 10 years past menopause (LPM; n = 14). Fasted skeletal muscle (vastus lateralis) samples were collected after 1 week administration of transdermal E2 or placebo, in random cross-over design.Results:Compared with EPM, LPM had reduced skeletal muscle ERα and ERβ nuclear protein. Short-term E2 treatment did not change nuclear ERα or ERβ, but decreased cytosolic ERα, so the proportion of ERα in the nucleus compared with the cytosol tended to increase. There was a group-by-treatment interaction (P < 0.05) for nuclear proliferator-activated receptor γ co-activator 1-α and phosphorylated adenosine monophosphate-activated protein kinase, such that E2 increased these proteins in EPM, but decreased these proteins in LPM.Conclusions:These preliminary studies of skeletal muscle from early and late postmenopausal women treated with E2 suggest there may be declines in skeletal muscle ER and changes in the E2-mediated regulation of cellular energy homeostasis with increasing time since menopause.

show abstract

“…43 Thus, a lack of estrogen in mice was related to obesity, decreasing fasting BGL, activating adenosine monophosphate protein kinase (AMPK), and reducing the expression of gluconeogenic genes, such as PCK in the liver. 44,45 However, this hypothesis could not be tested in our samples because estrogen circulating levels were not measured.…”

Section: Discussionmentioning

confidence: 96%

Association of PCK1 with Body Mass Index and Other Metabolic Features in Patients With Psychotropic Treatments

Saigí-Morgui

Vandenberghe

Delacrétaz

et al. 2015

Journal of Clinical Psychopharmacology

View full text Add to dashboard Cite

Weight gain is a major health problem among psychiatric populations. It implicates several receptors and hormones involved in energy balance and metabolism. Phosphoenolpyruvate carboxykinase 1 is a rate-controlling enzyme involved in gluconeogenesis, glyceroneogenesis and cataplerosis and has been related to obesity and diabetes phenotypes in animals and humans. The aim of this study was to investigate the association of phosphoenolpyruvate carboxykinase 1 polymorphisms with metabolic traits in psychiatric patients treated with psychotropic drugs inducing weight gain and in general population samples. One polymorphism (rs11552145G > A) significantly associated with body mass index in the psychiatric discovery sample (n = 478) was replicated in 2 other psychiatric samples (n1 = 168, n2 = 188), with AA-genotype carriers having lower body mass index as compared to G-allele carriers. Stronger associations were found among women younger than 45 years carrying AA-genotype as compared to G-allele carriers (-2.25 kg/m, n = 151, P = 0.009) and in the discovery sample (-2.20 kg/m, n = 423, P = 0.0004). In the discovery sample for which metabolic parameters were available, AA-genotype showed lower waist circumference (-6.86 cm, P = 0.008) and triglycerides levels (-5.58 mg/100 mL, P < 0.002) when compared to G-allele carriers. Finally, waist-to-hip ratio was associated with rs6070157 (proxy of rs11552145, r = 0.99) in a population-based sample (N = 123,865, P = 0.022). Our results suggest an association of rs11552145G > A polymorphism with metabolic-related traits, especially in psychiatric populations and in women younger than 45 years.

show abstract

Parenteral 17beta-estradiol decreases fasting blood glucose levels in non-obese mice with short-term ovariectomy

Cited by 46 publications

References 50 publications

Estrogen and n-3 polyunsaturated fatty acid supplementation have a synergistic hypotriglyceridemic effect in ovariectomized rats

Estrogen and n-3 polyunsaturated fatty acid supplementation have a synergistic hypotriglyceridemic effect in ovariectomized rats

Time since menopause and skeletal muscle estrogen receptors, PGC-1α, and AMPK

Association of PCK1 with Body Mass Index and Other Metabolic Features in Patients With Psychotropic Treatments

Contact Info

Product

Resources

About